Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Cytek Biosciences, Inc. (CTKB : NSDQ)

• Company Description    Cytek Biosciences Inc provides cell analysis solutions. The company developed high-resolution, high-content and high-sensitivity cell analysis technology called Full Spectrum Profiling. Cytek Biosciences Inc is based in FREMONT, Calif. Number of Employees: 702

• Price / Volume Information    Yesterday's Closing Price: $5.59 Daily Weekly Monthly 20 Day Moving Average: 1,372,346 shares Shares Outstanding: 129.98 (millions) Market Capitalization: $726.60 (millions) Beta: 1.16 52 Week High: $6.21 52 Week Low: $3.31 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -2.44% -1.41% 12 Week 29.70% 26.53% Year To Date 10.69% -3.95%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 47215 Lakeview Blvd. - Fremont,CA 94538 USA ph: 877-922-9835 fax: - investors@cytekbio.com https://cytekbio.com

• General Corporate Information    Officers Wenbin Jiang - President and Chief Executive Officer William McCombe - Chief Financial Officer Ming Yan - Chief Technology Officer and Director Jack Ball - Director Richard Chin - Director Peer Information Cytek Biosciences, Inc. (CORR.) Cytek Biosciences, Inc. (RSPI) Cytek Biosciences, Inc. (CGXP) Cytek Biosciences, Inc. (BGEN) Cytek Biosciences, Inc. (GTBP) Cytek Biosciences, Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 23285D109 SIC: 3826 Fiscal Year Fiscal Year End: December Last Reported Quarter: 06/01/26 Next Expected EPS Date: 11/04/26 Share - Related Items Shares Outstanding: 129.98 Most Recent Split Date: (:1) Beta: 1.16 Market Capitalization: $726.60 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.02 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-0.30 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 1.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 11/04/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 2.24 Price/Cash Flow: - Price / Sales: 3.52 EPS Growth vs. Year Ago Period: -125.00% vs. Previous Quarter: 40.00% Sales Growth vs. Year Ago Period: 5.57% vs. Previous Quarter: 9.07% ROE 09/30/26 - - 06/30/26 - -12.40 03/31/26 - -10.07 ROA 09/30/26 - - 06/30/26 - -9.17 03/31/26 - -7.56 Current Ratio 09/30/26 - - 06/30/26 - 4.48 03/31/26 - 4.69 Quick Ratio 09/30/26 - - 06/30/26 - 3.86 03/31/26 - 4.07 Operating Margin 09/30/26 - - 06/30/26 - -20.55 03/31/26 - -17.58 Net Margin 09/30/26 - - 06/30/26 - -38.98 03/31/26 - -36.25 Pre-Tax Margin 09/30/26 - - 06/30/26 - -19.75 03/31/26 - -17.61 Book Value 09/30/26 - - 06/30/26 - 2.49 03/31/26 - 2.54 Inventory Turnover 09/30/26 - - 06/30/26 - 1.91 03/31/26 - 1.98 Debt-to-Equity 09/30/26 - - 06/30/26 - 0.00 03/31/26 - 0.00 Debt-to-Capital 09/30/26 - - 06/30/26 - 0.08 03/31/26 - 0.12

Powered by Zacks Investment Research ©